Protein kinase C inhibitors (Q34457430)

2 August 2017

1 reference

title

Protein kinase C inhibitors (English)

1 reference

2 August 2017

Helen C Swannie

1

1 reference

PubMed ID

11734112

2 August 2017

Stanley B Kaye

series ordinal

2

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

Current Oncology Reports

1 reference

2 August 2017

4

1 reference

2 August 2017

37-46

1 reference

2 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-002-0046-7

2 August 2017

0 references

cites work

Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0046-7

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0046-7

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0046-7

A phase II study of bryostatin 1 in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0046-7

Small molecule modulators of cyclin-dependent kinases for cancer therapy

21 January 2018

1 reference

12 December 2020

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.

1 reference

12 December 2020

Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture

1 reference

12 December 2020

Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells

1 reference

12 December 2020

Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans

1 reference

12 December 2020

Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells.

1 reference

12 December 2020

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

12 December 2020

A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.

1 reference

12 December 2020

Phase II evaluation of bryostatin-1 in metastatic melanoma

1 reference

12 December 2020

Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation

1 reference

12 December 2020

Modulation of protein kinase C in antitumor treatment

1 reference

12 December 2020

28 Use and specificity of staurosporine, UCN-O1, and calphostin C as protein kinase inhibitors

1 reference

12 December 2020

Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital.

1 reference

12 December 2020

Protein kinase C modulation and anticancer drug response

1 reference

12 December 2020

Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.

1 reference

12 December 2020

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

12 December 2020

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

12 December 2020

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

1 reference

12 December 2020

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01

1 reference

12 December 2020

UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation

1 reference

12 December 2020

Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists

1 reference

12 December 2020

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

1 reference

12 December 2020

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

1 reference

12 December 2020

Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters.

1 reference

12 December 2020

The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients

1 reference

12 December 2020

Protein kinase C: a worthwhile target for anticancer drugs?

1 reference

12 December 2020

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

1 reference

12 December 2020

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

12 December 2020

Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta

1 reference

12 December 2020

Phase Ib trial of bryostatin 1 in patients with refractory malignancies

1 reference

12 December 2020

7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53

1 reference

12 December 2020

Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue

1 reference

12 December 2020

Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development.

1 reference

12 December 2020

PKC412--a protein kinase inhibitor with a broad therapeutic potential

1 reference

12 December 2020

A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin

1 reference

12 December 2020

Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells

1 reference

12 December 2020

Telomerase is controlled by protein kinase Calpha in human breast cancer cells

1 reference

12 December 2020

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

1 reference

12 December 2020

The role of protein kinase C in cell surface signal transduction and tumour promotion

1 reference

12 December 2020

Clinical and radiographic response in three children with recurrent malignant cerebral tumors with high-dose tamoxifen.

1 reference

12 December 2020

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1

1 reference

12 December 2020

Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein

1 reference

12 December 2020

Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients

1 reference

12 December 2020

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition

1 reference

12 December 2020

Linking protein kinase C to cell-cycle control

1 reference

12 December 2020

Biology of the protein kinase C family

1 reference

12 December 2020

Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro

1 reference

12 December 2020

Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU.

1 reference

12 December 2020

Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2

1 reference

12 December 2020

Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin

1 reference

12 December 2020

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway

1 reference

12 December 2020

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer

1 reference

12 December 2020

Antisense therapy in oncology: new hope for an old idea?

1 reference

12 December 2020

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

12 December 2020

P-glycoprotein, multidrug resistance and protein kinase C.

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study

1 reference

12 December 2020

10.1007/S11912-002-0046-7

Identifiers

DOI

1 reference

PubMed ID

11734112

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

11734112